AR045870A1 - Terapia de combinacion para la infeccion de virus de hepatitis c - Google Patents

Terapia de combinacion para la infeccion de virus de hepatitis c

Info

Publication number
AR045870A1
AR045870A1 ARP040103677A ARP040103677A AR045870A1 AR 045870 A1 AR045870 A1 AR 045870A1 AR P040103677 A ARP040103677 A AR P040103677A AR P040103677 A ARP040103677 A AR P040103677A AR 045870 A1 AR045870 A1 AR 045870A1
Authority
AR
Argentina
Prior art keywords
hepatitis
virus infection
combination therapy
combinations
therapeutic combinations
Prior art date
Application number
ARP040103677A
Other languages
English (en)
Inventor
Ene Ette
John J Alam
Robert Stephen Kauffman
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of AR045870A1 publication Critical patent/AR045870A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Combinaciones terapéuticas que comprenden VX-497, rebavirina, e interferón. Métodos que utilizan estas combinaciones terapéuticas para el tratamiento de la infección de virus hepatitis C o reducción de uno o más síntomas de la misma en un paciente y Kits que comprenden esas combinaciones.
ARP040103677A 2003-10-11 2004-10-08 Terapia de combinacion para la infeccion de virus de hepatitis c AR045870A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51073303P 2003-10-11 2003-10-11

Publications (1)

Publication Number Publication Date
AR045870A1 true AR045870A1 (es) 2005-11-16

Family

ID=34465143

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103677A AR045870A1 (es) 2003-10-11 2004-10-08 Terapia de combinacion para la infeccion de virus de hepatitis c

Country Status (17)

Country Link
US (1) US20050112093A1 (es)
EP (1) EP1670462A1 (es)
JP (1) JP2007508326A (es)
KR (1) KR20060120037A (es)
CN (1) CN1882335A (es)
AR (1) AR045870A1 (es)
AU (1) AU2004281747A1 (es)
BR (1) BRPI0415249A (es)
CA (1) CA2541857A1 (es)
IL (1) IL174864A0 (es)
MX (1) MXPA06004077A (es)
NO (1) NO20062104L (es)
PE (1) PE20050477A1 (es)
RU (1) RU2006115916A (es)
TW (1) TW200528104A (es)
WO (1) WO2005037274A1 (es)
ZA (1) ZA200602912B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9712544B1 (pt) 1996-10-18 2013-10-22 Inibidores de proteases de serina, composição farmacêutica compreendendo os mesmos e seus usos
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US20120201883A1 (en) * 2004-05-21 2012-08-09 Accu-Break Technologies, Inc Antiviral compositons
MY141025A (en) * 2004-10-29 2010-02-25 Vertex Pharma Dose forms
NZ565540A (en) * 2005-08-02 2011-06-30 Vertex Pharma Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
EP1993994A2 (en) 2006-03-16 2008-11-26 Vertex Pharmceuticals Incorporated Deuterated hepatitis c protease inhibitors
NZ579295A (en) * 2007-02-27 2012-03-30 Vertex Pharma Inhibitors of serine proteases
FR2928146B1 (fr) * 2008-02-28 2010-02-19 Saint Gobain Isover Produit a base de fibres minerales et son procede d'obtention.
KR20110054003A (ko) * 2008-09-17 2011-05-24 베링거 인겔하임 인터내셔날 게엠베하 Ｈｃｖ ｎｓ3 프로테아제 억제제와 인터페론 및 리바비린의 병용물
JP2012517478A (ja) * 2009-02-12 2012-08-02 バーテックス ファーマシューティカルズ インコーポレイテッド ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、ｈｃｖ組合せ治療剤
JPWO2011001897A1 (ja) * 2009-06-30 2012-12-13 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 難治性のｃ型慢性肝炎の治療のための薬剤及び方法
WO2011014882A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
KR20120106942A (ko) 2009-10-30 2012-09-27 베링거 인겔하임 인터내셔날 게엠베하 Ｂｉ２０１３３５, 인터페론 알파 및 리바비린을 포함하는 ｈｃｖ 병용 치료요법을 위한 투여 용법
US8853176B2 (en) 2011-10-21 2014-10-07 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
WO2017062840A1 (en) * 2015-10-09 2017-04-13 Trek Therapeutics, Pbc Combination therapy for the treatment of hepatitis c virus
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2017223178A1 (en) * 2016-06-21 2017-12-28 Trek Therapeutics, Pbc Treating viral infections with impdh inhibitors
WO2018169283A1 (ko) * 2017-03-14 2018-09-20 국립암센터 C형 간염 바이러스 질환 치료를 위한 리고세르팁의 신규 용도
CN109745315B (zh) * 2019-03-08 2021-04-16 中国农业科学院兰州兽医研究所 一种Merimepodib在制备预防口蹄疫病毒感染的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0004421A3 (en) * 1996-04-23 2002-10-28 Vertex Pharmaceuticals Inc Cam Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme
WO1999059621A1 (en) * 1998-05-15 1999-11-25 Schering Corporation Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection
US6824769B2 (en) * 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
WO2003101199A1 (en) * 2002-05-31 2003-12-11 Schering Corporation Combination therapy for rna virus infections involving ribavirin and impdh inhibitors

Also Published As

Publication number Publication date
BRPI0415249A (pt) 2006-12-12
AU2004281747A1 (en) 2005-04-28
RU2006115916A (ru) 2007-12-10
US20050112093A1 (en) 2005-05-26
EP1670462A1 (en) 2006-06-21
ZA200602912B (en) 2007-06-27
KR20060120037A (ko) 2006-11-24
CA2541857A1 (en) 2005-04-28
TW200528104A (en) 2005-09-01
IL174864A0 (en) 2008-04-13
MXPA06004077A (es) 2006-06-27
WO2005037274A1 (en) 2005-04-28
PE20050477A1 (es) 2005-08-24
NO20062104L (no) 2006-05-10
JP2007508326A (ja) 2007-04-05
CN1882335A (zh) 2006-12-20

Similar Documents

Publication Publication Date Title
AR045870A1 (es) Terapia de combinacion para la infeccion de virus de hepatitis c
BRPI0513370A (pt) uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv)
CY1116069T1 (el) Θεραπευτικη αγωγη της διαμεσης κυστιτιδας με υψηλη δοση θειικης χονδροϊτινης
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
DK1853250T3 (da) Kombinationer og måder til indgivelse af terapeutiske midler og kombinationsterapi
BRPI0415935A (pt) combinações para tratamento de hcv
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
RS52942B (en) TREATMENT OF TYPE 2 DIABETES BY THE COMBINATION OF DPIV IHIBITORS AND METFORMIN OR THIAZOLIDINDION
ATE414514T1 (de) Kombinationen, ein antidiarrhoikum und epothilon oder ein epothilonderivat enthaltend
CY1110437T1 (el) Χρηση παραγωγων καστανοσπερμινης για την θεραπεια της ηπατιτιδας c
ATE475423T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
ECSP066805A (es) Compuestos silinano como inhibidores de cisteína proteasa
MXPA04006572A (es) Terapia de combinacion antivirica.
AR043660A1 (es) El tratamiento de la enfermedad de alzheimer
WO2004004653A3 (en) Methods for treating psychosis associated with interferon-alpha therapy
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling
NO20055512L (no) Terapi eller prevensjon av respiratoriske, virale infeksjoner med alfa-tyimosinpeptider
BR0317539A (pt) Métodos e composições para o tratamento de infecções por vìrus da herpes usando inibidores seletivos da ou ciclooxigenase-2 ou inibidores da ciclooxigenase-2 em combinação com agentes antivirais
UA90477C2 (ru) Способ лечения гепатита с (варианты)
NO20053189L (no) HVC-kombinasjonsterapi.
NO20080495L (no) PEG-IFN-alfa og ribavirin for HBV-behandling
WO2004006843A3 (en) Combination therapies with l-fmau for the treatment of hepatitis b virus infection
GB0220257D0 (en) Vaccine
UY28555A1 (es) Terapia de combinación para la infección de hcv
ATE447944T1 (de) Verwendung von formoterol in der prophylaktischen und/oder therapeutischen behandlung von muskelschwund und/oder kachexie-syndrom im zusammenhang mit katabolischen zuständen bei bestimmten krankheiten, wie z.b. krebs, aids, infektionen, diabetes und andere

Legal Events

Date Code Title Description
FA Abandonment or withdrawal